The Federal Circuit appeal in Merck Sharp & Dohme B.V., Merck Sharp & Dohme, LLC v. Aurobindo Pharma USA, Inc. et al., concerns whether patent term extension (PTE) for regulatory delay, in particular delay for FDA drug...more
11/1/2023
/ Appeals ,
FDA Approval ,
Food and Drug Administration (FDA) ,
Intellectual Property Protection ,
Patent Litigation ,
Patent Registration ,
Patent Reissue Applications ,
Patent Term Adjustment ,
Patent Term Extensions ,
Patents ,
Pharmaceutical Patents ,
USPTO